Pharmasset Initiates Phase 2b Clinical Trial Of PSI-7977 For Chronic Hepatitis C Genotypes 1, 2, And 3

Links shared publicly online about this topic.

  • 922
    total visits

Pharmasset Initiates Phase 2b Clinical Trial Of PSI-7977 For Chronic Hepatitis C Genotypes 1, 2, And 3

medicalnewstoday.com —

Pharmasset, Inc. (Nasdaq: VRUS) announced that dosing has begun in a Phase 2b study of PSI-7977, a nucleotide analog polymerase inhibitor for the treatment of chronic hepatitis C (HCV). The trial

View full resource at medicalnewstoday.com

Tags: Liver, Liver Condition, Hepatitis, Hepatitis C, Clinical Trial

  • Share

Most Recently Shared on August 25, 2010 at 5:00 pm By:

mnt_pharma MNT Pharma News

Pharmasset Initiates Phase 2b Clinical Trial Of PSI-7977 For Chronic Hepatitis C Genotypes 1, 2, And 3 http://mnt.to/3HPd

2 years ago...

Reply

Retweet

Favorite

Also Shared By:

MNT Liver Disease MNT Liver Disease

MNT Clinical Trials MNT Clinical Trials

Advertisement